O May 22, GT Advanced Technologies Inc. (NASDAQ:GTAT) reported its results for the Q1 of financial year 2014, that ended on 29 March 2014. Revenue for the Q1 was $22.5M, including $13.2 million in PV, $5.6M for its sapphire segment & $3.7 million for the poly- silicon segment. This revenue compares to the $32.6M of revenue in the Q4 of the calendar 2013 & $57.8M of revenue in the Q1 of financial year 2013. The non-GAAP gross-profit for the Q1 was $1.9M, or 8.5% of revenue, in comparison to $6.8M or 21.0% of revenue in the Q4 of calendar 2013 & $14.3 million, or 24.7% of revenue for the Q1 of the calendar 2013. GT Advanced Technologies Inc (NASDAQ:GTAT) net profit margin is -40.00% and weekly performance is 14.83%. On last trading day company shares ended up $15.95. Analysts mean target price for the company is $20.67. GT Advanced Technologies Inc (NASDAQ:GTAT) distance from 50-day simple moving average (SMA50) is -2.05%.
Array BioPharma Inc. (NASDAQ:ARRY) a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced the appointments of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer and Robert E. Winkler, M.D., as Vice President of Clinical Research and Development. Dr. Saccomano will oversee Array’s discovery efforts and chemistry, manufacturing and controls (CMC) activities as a member of the executive management team, reporting to Array’s Chief Executive Officer, Ron Squarer. Dr. Winkler will be responsible for leading the company’s clinical science and operations activities, including its late-stage multiple myeloma program, filanesib, reporting to Array’s Chief Medical Officer, Michael Needle, M.D. Array Biopharma Inc (NASDAQ:ARRY) shares advanced 5.13% in last trading session and ended the day on $4.10. Gross Margin is 32.50% and its return on assets is -55.10%. Array Biopharma Inc (NASDAQ:ARRY) quarterly performance is -18.65%.
On May 6, MicroVision, Inc. (NASDAQ:MVIS) a leader in innovative ultra-miniature projection display technology, announced its operating and financial results for the first quarter of 2014 and the advancement of its 2014 business objectives. During the first quarter, MicroVision raised $12.8 million net of issuance costs in an offering of common stock and warrants for general corporate purposes. MicroVision has continued its aggressive management of cash used in operations with a reduction in the quarter of 16 percent compared to the same period in 2013. Microvision, Inc. (NASDAQ:MVIS) shares moved up 6.47% in last trading session and was closed at $1.81, while trading in range of $1.69 – $1.87. Microvision, Inc. (NASDAQ:MVIS) year to date (YTD) performance is 37.12%.
Rubicon Technology Inc (NASDAQ:RBCN) was upgraded by analysts at Oppenheimer from an “underperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday,TheFlyOnTheWall.com reports. The analysts noted that the move was a valuation call. Rubicon Technology, Inc. (NASDAQ:RBCN) ended the last trading day at $7.93. Company weekly volatility is calculated as 3.95% and price to cash ratio as 3.28. Rubicon Technology, Inc. (NASDAQ:RBCN) showed a positive weekly performance of 8.93%.
Move, Inc. (NASDAQ:MOVE) the leader in providing consumers the most accurate U.S. residential listings online, promotes Luke Glass to the new position of executive vice president of industry platforms. Glass is responsible for leading the company’s real estate industry relations efforts and supporting Move’s industry strategy. Move Inc. (NASDAQ:MOVE) net profit margin is -1.90% and weekly performance is 20.71%. On last trading day company shares ended up $12.30. Analysts mean target price for the company is $18.67. Move Inc. (NASDAQ:MOVE) distance from 50-day simple moving average (SMA50) is 10.08%.